ArticleHuman vaccines & immunotherapeutics2021
Incidence and disease burden of community-acquired pneumonia in southeastern China: data from integrated medical resources.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 21 citations in OpenAlex.
- Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60-70 years in Shanghai, China.Frontiers in immunology · 2025Trial
- Changes in 23-valent pneumococcal polysaccharide vaccination rate and associated factors in 2022 and 2024 among community-based older adults in Shanghai, China.Human vaccines & immunotherapeutics · 2026Article
- Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China.Infectious medicine · 2026Article
- Estimating the economic burden of lower respiratory infections in China from 2020 to 2040: a health-augmented macroeconomic modelling study.The Lancet regional health. Western Pacific · 2026Article
- Bacterial co-detection is associated with higher multidrug-resistantJAC-antimicrobial resistance · 2026Article
- Incidence of community-acquired pneumonia among adults between 2016 and 2023: an observational cohort study.Epidemiology and infection · 2026Observational
- Economic burden ofFrontiers in public health · 2026Article
- Development and internal validation of a nomogram for predicting the severity of community-acquired pneumonia in children.Frontiers in cellular and infection microbiology · 2026Article
- Development and validation of a pneumonia severity prediction model using AI analysis of abdominal and paravertebral intramuscular fat on chest CT in COVID-19 patients.Journal of thoracic disease · 2025Article
- Clinical evaluation of two pathogen enrichment approaches for next-generation sequencing in the diagnosis of lower respiratory tract infections.Microbiology spectrum · 2025Article
- Feasibility of Absent in Melanoma 2 as a Serological Marker in Relation to Complicated Community-Acquired Pneumonia in Children: A Prospective Cohort Study.International journal of general medicine · 2025Article
- Preventive effects of 23-valent pneumococcal polysaccharide vaccine on community-acquired pneumonia hospitalization in older individuals in China: A case-control study.Human vaccines & immunotherapeutics · 2024Article
- Article
- Relationships between human serum albumin levels and septic shock, in-hospital, and out-of-hospital mortality in elderly patients with pneumonia in different BMI ranges.Pneumonia (Nathan Qld.) · 2024Article
- Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Incidence of community-acquired pneumonia among children under 5 years in Suzhou, China: a hospital-based cohort study.BMJ open · 2024Observational
- Exploring the Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Unexplained Pulmonary Infection.International journal of general medicine · 2024Article
- Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatinFrontiers in pharmacology · 2024Article
- Shen-Ling-Bai-Zhu-San Enhances the Antipneumonia Effect of Cefixime in Children by Ameliorating Gut Microflora, Inflammation, and Immune Response.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Association between the Severity of Sarcopenia and Pneumonia in Patients with Stable Schizophrenia: A Prospective Study.The journal of nutrition, health & aging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community-acquired pneumonia (CAP) is a lower respiratory tract infection. It is one of the commonest infectious diseases and the third leading cause of death worldwide. However, the epidemiological profiles of CAP in southeastern China are unknown. Data of inpatients and outpatients diagnosed with CAP from January 1, 2015 to December 31, 2020 were obtained from the National Healthcare Big Data in Fuzhou (Fuzhou Database). This database covers medical data from 37 hospitals and 159 community health service stations. The incidence rate, treatment pattern, and direct medical costs of CAP were assessed using clinical data. A total of 8,156,237 patients were enrolled, with a mean age of 33.72 ± 20.88 years. The overall incidence rate of CAP was 3.13 (95% confidence interval [CI]: 3.11-3.15) per 1000 person-years (PY), with 15.97 (95% CI: 15.85-16.08) per 1000 PY in children below 5 years old and 2.62 (95% CI: 2.57-2.66) per 1000 PY in the elderly ≥60 years. The cost per outpatient was $242.83 ± 341.62, and the cost per inpatient was $4,530.4 ± 9,151.68. The three most used therapeutic drugs in patients with CAP are cefotaxime, moxifloxacin, and azithromycin. In addition, despite the ability of both imported and domestic pneumococcal conjugate vaccines to reduce the incidence rate of CAP, the current vaccination coverage rates were relatively low. We suggest that more attention should be paid to the disease burden of CAP, especially due to its great economic burden in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.